Substituted pyridine and pyrazine BMI-1 inhibitors
申请人:PTC Therapeutics, Inc.
公开号:US10584115B2
公开(公告)日:2020-03-10
Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
本文描述了可抑制 B 细胞特异性莫隆尼鼠白血病病毒整合位点 1(Bmi-1)蛋白的功能和降低其水平的胺取代吡啶和吡嗪化合物及其形式,以及使用它们抑制 Bmi-1 功能和降低 Bmi-1 水平以治疗由 Bmi-1 介导的癌症的方法。
SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS
申请人:PTC Therapeutics, Inc.
公开号:EP3071553A1
公开(公告)日:2016-09-28
[EN] SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS<br/>[FR] INHIBITEURS DE BMI-1 À BASE DE PYRIDINE ET DE PYRAZINE SUBSTITUÉES
申请人:PTC THERAPEUTICS INC
公开号:WO2015076800A1
公开(公告)日:2015-05-28
Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of B -cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.